You are here

IPOs

Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4

Fierce Biotech

Fri, 10/11/24 - 09:32 am

CAMP4 Therapeutics

CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans

Fierce Biotech

Mon, 10/7/24 - 09:58 pm

CAMP4 Therapeutics

Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape

Fierce Biotech

Thu, 10/3/24 - 10:32 am

hypoparathyroidism

Zephyrm rides IPO updraft toward Hong Kong listing, seeking cash for phase 3 cell therapy trials

Fierce Biotech

Wed, 10/2/24 - 10:40 am

Zephyrm Bioscience

graft vs host disease

Respiratory disorder biotech Upstream Bio files for a $100 million IPO

Renaissance Capital

Wed, 09/18/24 - 11:10 pm

monoclonal antibodies

Kairos goes public with $6M IPO to fund trials of lead cancer drug

Fierce Biotech

Tue, 09/17/24 - 10:54 am

Kairos Therapeutics

Three biotechs raise $700M in rare burst of IPO activity

BioPharma Dive

Fri, 09/13/24 - 09:22 am

Bicara Therapeutics

Zenas BioPharma

MBX Biosciences

MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3

Fierce Biotech

Mon, 09/9/24 - 07:10 pm

MBX Biosciences

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Reuters

Fri, 09/6/24 - 10:55 am

Bicara Therapeutics

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO

Reuters

Fri, 09/6/24 - 10:54 am

Zenas BioPharma

Bristol Myers Squibb

BioAge files for IPO, plans pair of midstage obesity trials

Fierce Biotech

Wed, 09/4/24 - 11:40 am

clinical trials

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment

Motley Fool

Thu, 08/29/24 - 11:10 am

autoimmune diseases

Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

Fierce Biotech

Tue, 08/27/24 - 11:34 am

MBX files for IPO, seeking cash to take challenger to Ascendis' Yorvipath into phase 3

Fierce Biotech

Mon, 08/26/24 - 10:09 am

MBX Biosciences

Ascendis Pharma

Bicara and Zenas file for IPOs to push late-phase prospects toward finish line

Fierce Biotech

Fri, 08/23/24 - 10:57 am

Bicara Therapeutics

Zenas BioPharma

Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO

Reuters

Thu, 08/22/24 - 10:01 pm

Zenas BioPharma

Bristol Myers Squibb

Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO

Fierce Biotech

Thu, 08/15/24 - 11:48 am

Actuate Therapeutics

Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO

Fierce Biotech

Tue, 08/13/24 - 11:32 am

clinical trials

OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs

Fierce Biotech

Thu, 08/1/24 - 11:39 am

Biopharma Investment Activity Continued to Rise in Q2: J.P. Morgan

BioSpace

Wed, 07/31/24 - 11:21 pm

Pages